logo
Share SHARE
FONT-SIZE Plus   Neg

Shire's DERMAGRAFT Approved In Canada For Treating Diabetic Foot Ulcers

Shire Plc (SHP.L, SHPG) said its lead regenerative medicine product, DERMAGRAFT (human fibroblast-derived dermal substitute) secured regulatory approval from Health Canada as a class IV medical device for the treatment of diabetic foot ulcers (DFUs), a complication of diabetes.

Shire Regenerative Medicine plans to make DERMAGRAFT available in Canada in the first quarter of 2013, and will leverage Shire's current infrastructure and commercial knowledge of the Canadian healthcare system.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Uber Technologies Inc., the company behind the famous ride-sharing app, is expanding its pilot food delivery service program, UberEATS, to New York City and Chicago. Uber's new pilot program allows customers to order a meal that will be delivered to them within ten minutes. There is a $3 delivery... Standard Chartered said it is still reviewing whether to shift its headquarters out of London, at a time when banks in Britain face higher levy and regulatory costs. Tyson Foods Inc. (TSN) Tuesday said it plans to eliminate the use of human antibiotics from its chicken production, as the meat producing giant joins other peers who have taken similar steps in the wake of health concerns. Tyson Foods said it is striving to eliminate the use of antibiotics from its...
comments powered by Disqus
Follow RTT